Cogent Biosciences: Funding, Investors & Team (Sep 2026)
Pertinent Biosciences utilizes restrictive T-cell designing innovation in blend with growth focusing on antibodies to actuate the body's own resistant framework to battle disease. Unum's lead program, in view of its Antibody-Coupled T-cell Receptor (ACTR) innovation, is supposed to enter Phase I clinical testing before long to evaluate wellbeing and viability. Unum is looking for accomplices keen on utilizing the ACTR innovation to arm restrictive growth explicit antibodies with a T-cell to work on their restorative potential. The organization is settled in Cambridge, Massachusetts.
Cogent Biosciences has raised $350M across 3 funding rounds on record, the most recent an undisclosed round of $50.0M announced in Jun 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cogent Biosciences Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Cogent Biosciences Funding Rounds
Cogent Biosciences raised $150M in a Post-IPO Equity announced in Jun 2022.
1 years later, an undisclosed round of $150M was announced in Jun 2023.
2 years later, an undisclosed round of $50.0M was announced in Jun 2025.
Cogent Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Cogent Biosciences Funding Compared to Other Biotechnology Startups
Cogent Biosciences' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cogent Biosciences in Biotechnology and Cambridge
Companies Similar to Cogent Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Cogent Biosciences Funding FAQs
What does Cogent Biosciences do?
Pertinent Biosciences utilizes restrictive T-cell designing innovation in blend with growth focusing on antibodies to actuate the body's own resistant framework to battle disease. Unum's lead program, in view of its Antibody-Coupled T-cell Receptor (ACTR) innovation, is supposed to enter Phase I clinical testing before long to evaluate wellbeing and viability. Unum is looking for accomplices keen on utilizing the ACTR innovation to arm restrictive growth explicit antibodies with a T-cell to work on their restorative potential. The organization is settled in Cambridge, Massachusetts.
How much funding has Cogent Biosciences raised?
Cogent Biosciences has raised $350M across 3 rounds on record. The most recent is an undisclosed round of $50.0M announced in Jun 2025.
When did Cogent Biosciences last raise funding?
Cogent Biosciences' most recent funding round on record is an undisclosed round of $50.0M, announced in Jun 2025.
Who founded Cogent Biosciences?
FundedIQ lists Dario Campana (Founder) at Cogent Biosciences.
Where is Cogent Biosciences headquartered?
Cogent Biosciences is based in Cambridge, Massachusetts, United States.
How many employees does Cogent Biosciences have?
Cogent Biosciences is in the 101-250 employee band.
How does Cogent Biosciences' funding compare to other Biotechnology startups?
Cogent Biosciences' latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Cogent Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cogent Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.